Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells

详细信息    查看全文

• 作者：Fatemeh Mosaffa (12) mosaffaf@mums.ac.ir
  Fatemeh Kalalinia (12)
  Herman Lage (3)
  Jalil Tavakol Afshari (4)
  Javad Behravan (12) behravanj@mums.ac.ir
• 关键词：Multidrug resistance &#8211 ; ABCG2 &#8211 ; Proinflammatory cytokines &#8211 ; Gene regulation &#8211 ; Cervix cancer &#8211 ; Gastric cancer
• 刊名：Molecular and Cellular Biochemistry
• 出版年：2012
• 出版时间：April 2012
• 年：2012
• 卷：363
• 期：1-2
• 页码：385-393
• 全文大小：450.9 KB
• 参考文献：1. Teodori E, Dei S, Scapecchi S, Gualtieri F (2002) The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 57:385–415
  2. Choi CH (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5:30
  3. Huls M, Russel FG, Masereeuw R (2009) The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 328:3–9
  4. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A (2004) ABCG2:a transporter for all seasons. FEBS Lett 567:116–120
  5. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458–3464
  6. Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ, Germa-Lluch JR, Izquierdo MA (2002) Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198:213–219
  7. Ross DD, Karp JE, Chen TT, Doyle LA (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96:365–368
  8. Mao Q, Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J 7:E118–E133
  9. Allen JD, Schinkel AH (2002) Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1:427–434
  10. Ho EA, Piquette-Miller M (2006) Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 6:295–311
  11. Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439
  12. Haddad JJ (2002) Cytokines and related receptor-mediated signaling pathways. Biochem Biophys Res Commun 297:700–713
  13. Dinarello CA (2000) Proinflammatory cytokines. Chest 118:503–508
  14. Caruso C, Lio D, Cavallone L, Franceschi C (2004) Aging, longevity, inflammation, and cancer. Ann N Y Acad Sci 1028:1–13
  15. Wilson J, Balkwill F (2002) The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 12:113–120
  16. McRae MP, Brouwer KL, Kashuba AD (2003) Cytokine regulation of P-glycoprotein. Drug Metab Rev 35:19–33
  17. Assenat E, Gerbal-chaloin S, Maurel P, Vilarem MJ, Pascussi JM (2006) Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer? Eur J Cancer 42:785–792
  18. Vee ML, Lecureur V, Stieger B, Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 37:685–693
  19. Malekshah OM, Bahrami AR, Afshari JT, Mosaffa F, Behravan J (2011) Correlation between PXR and ABCG2 patterns of mRNA expression in a MCF7 breast carcinoma cell derivative upon induction by proinflammatory cytokines. DNA Cell Biol 30:25–31
  20. Mosaffa F, Lage H, Afshari JT, Behravan J (2009) Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res 58:669–676
  21. Tahara E (2008) Abnormal growth factor/cytokine network in gastric cancer. Cancer Microenviron 1:85–91. doi:
  22. Munagala R, Nagarajan B (2008) Alterations in cytokine levels in cervical carcinoma patients through radiation therapy. Current Science 94:1292–1296
  23. Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ (1993) Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 69:651–659
  24. Minderman H, Suvannasankha A, O’Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR (2002) Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59–65
  25. Elahian F, Kalalinia F, Behravan J (2009) Dexamethasone downregulates BCRP mRNA and protein expression in breast cancer cell lines. Oncol Res 18:9–15
  26. Kalalinia F, Elahian F, Behravan J (2010) Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J Cancer Res Clin Oncol 137:321–330
  27. Elahian F, Kalalinia F, Behravan J (2010) Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol 33:113–119
  28. Slaviero KA, Clarke SJ, Rivory LP (2003) Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4:224–232
  29. Evseenko DA, Paxton JW, Keelan JA (2007) Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 35:595–601
  30. Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Ronnblom A (2007) Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm Bowel Dis 13:291–297
  31. Poller B, Drewe J, Krahenbuhl S, Huwyler J, Gutmann H (2010) Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 30:63–70
  32. von Wedel-Parlow M, Wolte P, Galla HJ (2009) Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem 111:111–118
  33. Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, Ohnishi N, Yokoyama T (2006) Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemother Pharmacol 58:785–793
  34. Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M, Matsushima K (1992) Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J Biol Chem 267:22506–22511
  35. Lee G, Piquette-Miller M (2001) Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 79:876–884
  36. Kaszubiac A (2007) Adenoviraler Transfer von anti-MDR1 shRNAs Implikationen f眉r die Gentherapie multidrug-resistenter Tumoren. Ph.D.Thesis
  37. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH (1997) Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst 89:807–813
• 作者单位：1. Biotechnology Research Centers, Mashhad University of Medical Sciences, Mashhad, Iran2. Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P.O. Box: 91775-1365, Mashhad, IRAN3. Institute of Pathology, Charite鈥?Campus Mitte, Humboldt University, 10117 Berlin, Germany4. Immunology Research Centers, Mashhad University of Medical Sciences, Mashhad, Iran
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Biochemistry
  Medical Biochemistry
  Oncology
  Cardiology
  
• 出版者：Springer Netherlands
• ISSN：1573-4919

文摘

The ATP-binding cassette sub-family G member 2 (ABCG2) is implicated as a member of multidrug resistant proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. Pro-inflammatory cytokines, which are present within the micro-environment of tumors and inflammation, are able to modulate the expressions and activities of different drug transporters. This study was aimed to evaluate the short-term (72-h treatment) effects of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) on the expression and function of ABCG2 in cervix carcinoma and gastric cancer cells. Effects of pro-inflammatory cytokines on mRNA, protein expression, and function of ABCG2 were studied using real time RT-PCR and flow cytometry methods, respectively. HeLa cells treated with IL-1β, IL-6, or TNF-α showed decrements in ABCG2 mRNA levels without any changes in protein expression and function of ABCG2. IL-6 and TNF-α had no effects on mRNA, protein expression, and function of ABCG2 in EPG85-257 cells. Although IL-1β did not alter ABCG2 at mRNA or protein levels in EPG85-257 cells, it augmented function of ABCG2 in these cells. Mitoxantrone accumulation was also amplified in IL-1β-, IL-6- or TNF-α-treated HeLa cells and in IL-1β-treated EPG85-257 cells. In conclusion, pro-inflammatory cytokines were able to modulate the expression of ABCG2 at transcriptional and post-transcriptional levels in human cervix and gastric cancer cells.